Healthcare: Huntsworth wins pan-European drug brief

Huntsworth Health has strengthened its pan-European portfolio with a win for a pre-launch brand in the cardiovascular arena.

Uxbridge-based drug company Otsuka Pharmaceutical Europe has taken on Huntsworth for pan- European PR support without a competitive pitch. The agency has been brought on board to handle comms activity for the cardiovascular drug's launch into the heart failure market across Europe.

Huntsworth will target healthcare professionals as part of the brief. The activity will be handled from Huntsworth's Marlow office by medical comms associate divisional director Annabelle Sandeman.

The brief follows another cardiovascular account win last month.

Huntsworth has been hired by Japanese pharma company Daiichi-Sankyo following a competitive pitch against three undisclosed agencies (PRWeek, 28 February).

The agency has been briefed to launch the pharma firm's new hypertension drug into the market.

It was also appointed by drug company Novartis for its vaccines portfolio following a competitive pitch. Last week Huntsworth chief executive Lord Chadlington predicted that the group's healthcare arm would maintain its high level of growth (PRWeek, 14 March).

Last year, it reported 67 per cent year-on-year growth. Huntsworth as a whole posted a 23 per cent rise in profit before tax for 2007.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in